Marlies Sharkhawy

Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A

Eric S. Mullins, Oleksandra Stasyshyn, David Osman et al. · Haemophilia · 2016 · 80 citations · Full text

Medicine, Hematology, Pharmacokinetics +12

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski et al. · Journal of Clinical Immunology · 2011 · 76 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +12

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Clinical Immunology · 2016 · 50 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability

Richard L. Wasserman, Isaac Melamed, Lisa Kobrynski et al. · Immunotherapy · 2016 · 40 citations · Full text

Life Sciences, Immunology, Pediatrics +13

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial

Ralph A. Gruppo, Maria‐Fernanda López‐Fernández, Tung Wynn et al. · Haemophilia · 2019 · 31 citations · Full text

Medicine, Hematology, Perioperative Medicine +16